- Home
- FBIO vs MAIA Comparison
FBIO vs MAIA Comparison
Compare FBIO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- MAIA
- Stock Information
- Founded
- FBIO 2006
- MAIA 2018
- Country
- FBIO United States
- MAIA United States
- Employees
- FBIO N/A
- MAIA N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- FBIO Health Care
- MAIA Health Care
- Exchange
- FBIO Nasdaq
- MAIA Nasdaq
- Market Cap
- FBIO 53.5M
- MAIA 56.3M
- IPO Year
- FBIO N/A
- MAIA 2022
- Fundamental
- Price
- FBIO $2.12
- MAIA $1.58
- Analyst Decision
- FBIO Strong Buy
- MAIA
- Analyst Count
- FBIO 2
- MAIA 0
- Target Price
- FBIO $21.00
- MAIA N/A
- AVG Volume (30 Days)
- FBIO 204.0K
- MAIA 398.8K
- Earning Date
- FBIO 08-14-2025
- MAIA 08-11-2025
- Dividend Yield
- FBIO N/A
- MAIA N/A
- EPS Growth
- FBIO N/A
- MAIA N/A
- EPS
- FBIO N/A
- MAIA N/A
- Revenue
- FBIO $59,301,000.00
- MAIA N/A
- Revenue This Year
- FBIO $51.59
- MAIA N/A
- Revenue Next Year
- FBIO $44.74
- MAIA N/A
- P/E Ratio
- FBIO N/A
- MAIA N/A
- Revenue Growth
- FBIO N/A
- MAIA N/A
- 52 Week Low
- FBIO $1.33
- MAIA $1.40
- 52 Week High
- FBIO $2.36
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- FBIO 63.67
- MAIA 45.57
- Support Level
- FBIO $1.90
- MAIA $1.50
- Resistance Level
- FBIO $2.04
- MAIA $1.73
- Average True Range (ATR)
- FBIO 0.10
- MAIA 0.09
- MACD
- FBIO 0.02
- MAIA 0.01
- Stochastic Oscillator
- FBIO 81.40
- MAIA 42.86
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.